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1. Introduction 
Worldwide, carcinoma of the uterine cervix is one of the most common malignancies 
among women. Incidence rates of this disease vary from about 5 cases per 100 000 women 
per year in many industrialized countries to more than 50 per 100 000 in some developing 
nations. Approximately 80% of all cases occur in less-developed countries, because 
prevention programs are either non-existent or poorly conducted (WHO, 2009). 
Furthermore, in the less developed areas of the world, cervical cancer begins to strike 
significantly among women as young as 25-30 years of age, clearly identifying this disease 
as the cancer priority in women. 
Clinical epidemiology have clearly identified that the association between infection with 
high-risk types of human papillomavirus (HPV) and high-grade cervical cancer 
precursors as well as cervical cancer is very strong (Wright Jr., 2006). However, even high-
risk HPV infection are widespread in the world, the majority of HPV-associated lesions 
such as cervical intraepithelial neoplasia (CIN) will remain stable or spontaneously 
regress over time (zur Hausen, 2000; Ferenczy, 2001; Holowaty, 1999; Syrjanen, 1996), 
suggesting that other genetic and epigenetic events are likely to be involved in cervical 
carcinogenesis. Indeed, genomic alterations leading to tumor suppressor gene inactivation 
and/or oncogene activation are the critical pathways in the development and progression 
of cervical cancer as well as the other types of cancer. In this field, p53, p16 and E-
cadherin are important proteins that play critical role in the development and the 
progression of cervical cancer. 
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2. Human papillomavirus and cervical cancer 
Association between HPV and cervical lesions and cancer has started in 1970s’ years after 
the hypothesis that cervical cancer may arise from infections with the virus found in 
condylomata acuminata (zur Hausen, 1975; 1976). Then epidemiological and clinical studies 
have clearly demonstrated that HPV are the major etiologic agents of neoplasia of the 
cutaneous and mucosal epithelia; HPV positivity in cervical cancer is estimated to be 
between 90% and 95% (zur Hausen, 1991; Munoz, 2003). Currently, there is compelling 
evidence to indicate that the development of human cervical cancer without involvement of 
the specific HPV is exceptional. 
Up to now, more than 200 HPV genotypes were recensed, but the interest is focused only on 
30 types that are closely associated to cervical lesions. Among them, 15 HPV types have 
been classified as high risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82); 
three have been classified as probable high risk types (26, 53, and 66); and 12 have been 
classified as low risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108) (Munoz, 2003). 
Among the high risk HPV genotypes, HPV-16 is the most common in squamous cell 
carcinoma of the cervix (50–60%), followed by HPV-18, which is present in about 11–15% of 
cervical cancer cases (Munoz, 2003, Saranath, 2002).  
HPV genomes code for at least six different early and two late proteins. The structure of the 
genome and the characteristic properties of individual viral proteins have been well 
reviewed (zur Hausen, 2000; Stanley, 2010; Moody & Laimins, 2010). High-risk HPVs code 
for at least three proteins with growthstimulating and transforming properties (E5, E6, and 
E7). 
In the pathogenesis of cervical carcinoma we can identify three major factors. Two of them 
are related to the HPV presence, the effects of viral E6 and E7 proteins, and the 
consequences of HPV DNA integration in the cellular genome. The third factor is the 
accumulation of cellular genetic damage, not related to HPV, needed for tumour 
development (Lazo, 1999). 
Viral DNA integrated into host genome is found in all cases of cervical carcinoma (Bosch, 
1995), their metastasis and derivative cell lines (Cullen, 1991). 
HPV DNA integration into host chromatin is usually a necessary event in the pathogenesis 
of HPV-related cervical cancer. It is one of the key stages in malignant progression and is 
therefore a potential biomarker that precedes invasive disease. 
Many studies have demonstrated that the integrated HPV DNA is linearized between the E1 
and L1 genes. Upon viral integration, variable parts of the HPV genome are disrupted; 
fragments containing E2 and E4 ORFs are missing whereas the entire E1, E6 and E7 ORFs 
are integrated and retained (Raybould, 2011).  
HPV viral integration is made in such way that the viral regulatory region and the E6 and 
E7 genes are expressed from viral promoters, but with a different regulation, in which 
cellular factors might play an important role (Lazo, 1999; Raybould, 2011). In the normal 
HPV life-cycle expression of E5, E6 and E7 is tightly regulated within cells that are destined 
to be lost from surface epithelial layers, such that they do not pose a carcinogenic threat 
(Raybould, 2011) 
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E5 expression enhances oncogenic potential (Stoppler, 1996; Maufort, 2010) but the exact 
function of E5 remains poorly understood. E6 and E7 expression is essential for maintenance 
of the transformed state and malignant progression (Bosch, 1990; von Knebel Doeberitz, 
1988).  
The implication of E6 and E7 proteins in cervical cancer progression is mainly due 
through their interactions with hTERT, p53 and Retinoblastoma protein (pRB). hTERT is a 
catalytic subunit of Telomerase that acts to synthesise telomere ends of linear 
chromosomes during DNA replication. p53 is a transcription factor that regulates cell 
cycle arrest, apoptosis, senescence, DNA repair and cell metabolism; p53 activity is 
inhibited by ubiquitin ligase which also ubiquitinates p53 to initiate p53 degradation 
(Figure 1). In addition to inducing the rapid degradation of p53, E6 also binds to and 
degrades FADD, preventing the transmission of apoptotic signals via the Fas pathway 
(Filippova, 2004).  
pRB is a tumour suppressor protein and interacts with transcription factor E2F to repress the 
transcription of genes required for the S phase of the cell cycle (Figure 1). E7 can also bind to 
other connected proteins such as p107 and p130 (Raybould, 2011).  
Currently vaccination based strategy is an alternative method showed to be amore effective 
and practical approach than the implementation of regular and periodic cytological 
screening. Today it is very well established that intervention with vaccines permits already 
the statement that essential precursor lesions of this cancer are efficiently prevented (Zur 
Hausen, 2009). 
 
Fig. 1. Schematic representation of E6 and E7 activities in cervical cells 
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3. p53 expression and polymorphism in cervical cancer 
The human tumour suppressor gene p53 plays a key role in the cell's response to genotoxic 
stress and loss of this 'guardian of the genome' is an important step in carcinogenesis. The 
highly significant tumour suppressor gene, p53, is implicated in a wide range of human 
cancers, and is a multifunctional protein that plays critical roles in cellular responses to 
DNA damage, cellular senescence and apoptosis to maintain genomic stability of a cell 
(Kashima, 2007). p53 encodes a transcription factor at the centre of a network that maintains 
cellular integrity by the inhibition of cell growth and stimulation of apoptosis in response to 
cellular stresses such as DNA damage (Scheffner, 1990). 
Because mutation of the p53 gene is a relatively rare event in cervical cancer, p53 activity is 
mainly inhibited by the viral oncoprotein E6. It’s clearly identified that abrogation of p53 
function by the E6 protein of HPV is thought to be one of the major events in cervical 
carcinogenesis (Soussi, 2001). The viral E6 protein interacts with protein p53 and inhibits its 
activity, followed by proteolytic degradation through the ubiquitin pathway (Scheffner, 
1990; Werness, 1990).  
As shown if Figure 2, expression of p53 on cervical cancer biopsies showed that the p53 
immunoreactivity is detected especially in nuclei. The expression is greater in the peripheral 
cells of tumours.  
 
Fig. 2. Representative p53 immunohistochemical staining in epidermoid carcinoma 
Different studies showed that p53 expression did not correlate with tumour recurrence 
demonstrating that immunohistochemistry for p53 protein appears to provide no prognostic 
information for all patients with cervical cancer (Abd El All, 1999; Vasilescu, 2009; Abrahao, 
2011). However, it still remains a prognostic factor for the aggressive behavior of the 
tumour, when it exceeds more than 30% positivity in tumour cells nuclei (Vasilescu, 2009). 
Many studies, using different p53 monoclonal antibodies, have reported the lack of any 
association between p53 IHC expression and staging (Abd El All, 1999). Indeed, in HPV 
positive cervical carcinoma, the wild type p53 complex with E6 of HPV 16 or 18, is degraded 
and cannot be detected by IHC. In other cancers, Overexpression of p53 in tissues has 
generally been assumed to reflect accumulation of p53 mutations. 
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Several polymorphisms have been identified within the p53 gene, both in non-coding and 
coding regions and may represent an important contribution to cancer susceptibility and 
tumour behaviour (Costa, 2008). The common polymorphism is known at codon 72, with 
two alleles encoding either arginine (p53 Arg) or proline (p53 Pro) (Matlashewski, 1987). 
The genotype of p53 gene at codon 72 is detected by PCR with allele specific primers “ASP” 
that especially detects either the p53Pro or p53Arg allele. DNA is amplified in separate 
reactions with p53 Pro and p53 Arg primers. Example of resulting amplifications is reported 
in Figure 3. 
            M           p53 Arg/Arg              p53 Arg/Pro             p53 Pro/Pro  
 
Fig. 3. Analysis of p53 codon 72 polymorphism by PCR using allele specific primers  
Arg allele specific primers: 141 bp and Pro allele specific primers: 177 bp. M: 100 bp ladder. 
The Pro/Pro, Pro/Arg, and Arg/Arg frequencies have been reported in human cancers 
including lung, colorectal, breast, stomach, bladder, head and neck and oral, for their 
association with predisposition and subsequent increased susceptibility to the cancer. These 
studies have shown that the presence of Arg/Arg genotype has been associated with 
increased susceptibility to cervical cancer and Pro/Pro genotype is more frequent in lung 
cancers (Storey, 1998; Hamel, 2000; Tandle, 2001).  
This polymorphism occurs in the proline-rich domain of the p53 protein, which is necessary 
for the protein to fully induce apoptosis (Zhu, 2007). The functional difference between the 2 
alleles of this polymorphism is that the Arg/Arg genotype induces apoptosis with faster 
kinetics and suppresses transformation more efficiently than the Pro/Pro genotype (Kuroda, 
2007). In cervical cancer, different studies have investigated the effect of the codon 72 
polymorphism of p53 on the susceptibility to E6-mediated degradation. They reported that 
individuals homozygous for p53 Arg are more susceptible to HPV-associated carcinogenesis 
of the cervix than heterozygotes (Storey, 1998). However the relationship between the p53 
polymorphism and susceptibility of HPV infection as well as cervical cancer development is 
still unclear.  
Storey et al. (1998) showed that the codon 72 arginine variant of p53 encodes a protein that is 
more sensitive to HPV16 and HPV18 degradation than the proline variant. The biological 
and biochemical differences between the two p53 genotypes at codon 72 were demonstrated 
by a study showing that the arginine form of the protein was much more susceptible to HPV 
E6 mediated degradation than the proline form (Mitra, 2005; Oliveira, 2008). Moreover, 
Thomas et al. (1999), presented evidence that, in vitro, the p53 arginine variant induces 
apoptosis with faster kinetics and suppresses transformation more efficiently than the p53 
proline variant. These observations may have implications for the development of cancer in 
subjects harbouring p53 modified sequences and for the responsiveness of tumours to 
therapy. 
177bp 
141bp 
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The case-control study conducted in 113 cancerous lesions and 100 healthy women from 
Morocco highlighted the absence of any association between p53 polymorphism at codon 72 
and cervical cancer development (Meftah El Khair, 2009). However reported data on the 
prevalence of p53 polymorphism in cervical cancer patients are controversial and the ethnic 
group characteristics seem to be an important reason for discrepancies in the frequency of 
this polymorphism (Brenna, 2004; Wang, 1999; Wu, 2004; Pegoraro, 2002; Klug, 2001; Szarka, 
2000; Agorastos, 2000; Hildesheim, 1998; Bhattacharya, 2002). Moreover, other potential 
confounding factors should be also considered including the sample size, the source of DNA 
and the detection techniques used. Another important reason for these discrepant results 
could be misclassification of the p53 polymorphism, due to inter-laboratory variations in 
protocols, affecting the ability to detect p53 polymorphisms (Brenna, 2004; Govan, 2007; 
Sousa, 2007).  
4. Epigenetic alteration and cervical cancer 
Cancer is a multi-factor process. Molecular analysis of tumours reveals genetic and 
epigenetic abnormalities. Genetic mutations, which alter DNA sequence, lead to constitute 
activation of some oncogenes (as RAS and RAF genes) and inhibition of some tumour 
suppressors (as p53 gene). Epigenetic mutations (epimutations) lead often to gene silencing 
without altering the DNA sequence. Alteration in expression of key genes through aberrant 
epigenetic regulation can lead to initiation, promotion and maintenance of carcinogenesis, 
and is even implicated in the generation of drug resistance. The significance of epigenetic 
alterations is used as predictive biomarkers and as new targets of anticancer therapy. 
Genetic information may not be the only relevant source of information in order to 
understand the molecular basis of disease. Epigenetic information may hold the key to a 
better understanding of various pathological conditions (Chahwan, 2011). 
Epigenetic mechanisms are essential for normal development and maintenance of tissue-
specific gene expression patterns in mammals. These include embryonic development, 
transcription, chromatin structure, X-chromosome inactivation, genomic imprinting, and 
chromosome stability (Watanabe, 2010). Epigenetic dysregulation, which may be passed 
from one generation to the next, are believed to be implicated in the promotion of 
tumorigenesis in cancers through the downregulation of tumour repressor genes (Hidemi, 
2011). Epigenetic aberrations, often observed in tumours, include changes in DNA 
methylation and histone modifications that influence the chromatin states and impact gene 
expression patterns. Methylation of cytosine bases in DNA is the main epigenetic event and 
is involved in most cellular physiopathological processes (Watanabe, 2010).  
The CpG islands, where Cytosine and Guanine are connected by a phosphodiester bond, are 
shorts stretches of DNA in which the frequency of the CG sequence is higher than other 
regions. CpG islands are mostly located in the upstream promoter and exon 1 region of over 
half of human genes (Lo, 2008). In mammals, the methylation process is achieved by the 
DNA methyltransferase (DNMT), that catalyses the transfer of the methyl group from S-
adenosyl L-methionine (SAM) to the cytosine in 5’-CG-3’ sequence.  
In cancer, abnormal hypermethylation of gene promoter CpG islands induces 
transcriptional silencing of tumour suppressor genes (Lo, 2008) and is by far the best-
categorised epigenetic change. 
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Inactivation of tumour suppressor genes by promoter hypermethylation has been 
recognized to be at least as common as gene disruption by mutation in tumorigenesis (Jones, 
2002). 
Multiple genes are hypermethylated in primary carcinomas as well as in carcinoma cell line 
and the methylation profile has strong associations with genetic and clinicopathological 
features (Lind, 2004). 
HPV regulates the methylation status of genes involved in the cell cycle regulation, 
apoptosis, DNA repair, cell adhesion and migration, development and differentiation, 
cellular signalling and metabolism (Anita Szalmás, 2009). 
The HPV oncoprotein E7 control cellular proliferation pathways through epigenetic 
mechanisms. Recently, it has been shown that E7 bind directly to the DNMT1 and activate 
its DNA methyltransferase activity. This direct association may lead to aberrant methylation 
of the genome followed by cellular transformation as a result of tumour suppressor gene 
silencing (Burgers, 2007). E7 can induce viral replication also through epigenetic changes. E7 
inhibits HDAC (histone deacetylase) binding to the E2F promoter resulting in activation of 
expression and facilitates HPV replication (Longworth, 2005). 
HPV can epigenetically regulate cell cycle via down regulation of p16INK4A, an inhibitor of 
cyclin dependent phosphorylation and inactivation of Rb (retinoblastoma) tumour 
suppressor protein. The occurrence of p16INK4A promoter hypermethylation is very low in 
low grade of cervical cancer and it increases moderately with the severity of the 
carcinogenetic stages (Wong, 1999; Gustafson, 2004).  
Cyclin A1 (CCNA1) is involved in cell cycle regulation and in repair of DNA doublestrand 
breaks. Kitkumthorn et al. (2006) have evaluated the epigenetic status of cyclin A1 in HPV-
associated cervical cancer. The authors demonstrated that cyclin A1 methylation is common 
in cervical cancer and is specific to the invasive phenotype indicating that hypermethylation 
of promoter of cyclin A1 is a potential tumour marker for early diagnosis of invasive 
cervical cancer (Kitkumthorn, 2006). 
E-cadherin is a transmembrane glycoprotein that mediates interactions between adjacent 
epithelial cells. Hypermethylation of CpG islands in E-cadherin promoter regions is 
associated with suppressed transcriptional activity and it is particularly found in various in 
invasive cervical cancers (Kang S 2006).  
5. Study of gene promoter methylation 
For gene-specific methylation analysis, a large number of techniques have been developed. 
Most early studies used methylation sensitive restriction enzymes to digest DNA followed 
by Southern detection or PCR amplification. Recently, bisulfite reaction based methods have 
become very popular. In these techniques, analysis of DNA methylation is based on bisulfite 
treatment of genomic DNA, which converts cytosine to uracil, but methylated cytosines 
remain unaltered in this process. Several techniques have been applied to analyse bisulfite-
modified DNA, with variation in sensitivity, amount of DNA needed. However, PCR based 
techniques are the fast, simple and reliable methods to assess the methylation status of 
DNA. After PCR amplification, uracil will be converted to thymidine, which will be 
determined by direct PCR sequencing (bisulfite sequencing) or methylation specific PCR 
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(MSP-PCR) (Figure 4). In bisulfite sequencing, primers are designed not to contain any 
CpGs to avoid discrimination against methylated or unmethylated DNA. In MSP-PCR, two 
pairs of primers are designed, one of which is specific for methylated DNA (M) and the 
other for unmethylated DNA (U). 
After pyrosequencing or MSP-PCR, amplified fragments are usually cloned to determine the 
degree of methylation (Herman, 1996). 
Additionally, in order to identify unknown methylation hot-spots or methylated CpG 
islands in the genome, several of genome-wide screen methods have been invented such as 
Restriction Landmark Genomic Scanning for Methylation (RLGS-M), and CpG island 
microarray. 
 
Fig. 4. Schematic representation of bisulfite based modifications 
6. p16
INK4a
 expression in cervical cancer 
The cellular tumour suppressor protein p16 has a central function in the regulation of cell 
cycle activation. The p16INK4a, the product of CDKN2A gene is a negative regulatory protein 
that regulates the progression of eukaryotic cells through the G1 phase of the cell cycle 
(Serrano, 1997). p16INK4a is a component of p16INK4a-Cdk4-6/CyclinD-pRb signalling 
pathway and is perturbed in many cancers. In these tumours, the functions of p16INK4a may 
be lost due to mutations or suppression of its transcription by promoter methylation 
(Gonzalgo, 1998). In high risk-HPV positive cervical cancer, the oncogene E7 disrupts 
pRb/E2F interaction, releases active E2F and induces the pRb degradation (Liuet, 2006). The 
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existence of the regulatory feedback in the pRb/p16 pathway leads to an overexpression of 
p16INK4a in cervical tumours (Ivanova, 2007). Klaes el al. (2001) have shown that 
overexpression of p16INK4a is a specific marker for dysplastic and neoplastic epithelial cells 
in the cervix. They have clearly demonstrated that use of p16INK4a immunostaining allows 
precise identification of cervical lesions and significantly reduce false-negative and -positive 
interpretation in cervical cancer screening. For theses reasons, p16INK4a expression is usually 
used in cervical neoplasia diagnosis (Klaes, 2001).  
Many studies have analyzed the presence of p16INK4a in cervical neoplasia and have found a 
relationship between p16INK4a expression and cervical neoplasia; raising hope that p16INK4a 
could represent a specific and sensitive marker for cervical neoplasia (Klaes, 2001; Milde-
Langosch, 2001; Riethdorf, 2004). A representative p16INK4a immunohistochemical staining 
in epidermoid carcinoma is given in Figure 5. It is generally believed that p16INK4a functions 
as Cdk-inhibitor in the nucleus. Klaes et al. have showed that 58 of 60 invasive cervical 
carcinomas expressed p16INK4a both in nuclei and cytoplasm (Klaes, 2001). Theses findings 
were corroborated with published data from Moroccan cases. Indeed, p16INK4a staining by 
IHC in 53 cervical cancer biopsies from Morocco showed that 92.4% had high level of 
p16INK4a expression with a predominance of both nuclear and cytoplasmic staining (El 
Hamdani, 2010). 
 
(Intense Nuclear staining of p16INK4a) 
Fig. 5. Representative p16 immunohistochemical staining in epidermoid carcinoma sample 
On the other hand, Ivanova et al. (2007) have clearly demonstrated that in normal cells 
p16INK4a localizes mainly in nuclei, the loss of p16INK4a nuclear staining in favour of 
cytoplasmic staining have been observed earlier in different tumours including cervical 
carcinomas and cervical cancer cell lines. 
Loss of p16INK4a protein expression, leading to overcome cell cycle arrest at senescence and 
immortalization, could be studied by evaluating the methylation status of its promoter 
(Ivanova, 2007).  
Indeed, hypermethylation of the promoter region of a tumour suppressor gene has been 
increasingly recognized as an alternative mechanism for inactivation of function of a tumour 
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suppressor gene. In this topic, hypermethylation of the p16 gene has been suggested to be a 
shared epigenetic alteration in multiple human cancers, including cervical cancer (Esteller, 
2001).  
An example of MSP analysis of the promoter regions of p16INK4a after bisulfite treatment is 
given if Figure 6. Using MSP and/or bisulfite sequencing, hypermethylation of p16INK4a 
gene was observed in 19 to 61% of invasive cervical carcinoma (Ivanova, 2007, Nehls, 2008; 
Attaleb, 2009). However, hypermthylation of p16INK4a promoter region is absent in DNA 
specimens from normal cervical swabs as well as cervical cell lines such as SiHa, HeLa, 
C33A and Caski (Attaleb, 2009). 
Moreover, the increased risk for disease progression was independent from clinical and 
pathological factors, suggesting that p16INK4a gene promoter methylation is an early event in 
cervical cancer development.  
Moreover, in HPV induced cervical cancer, the cell cycle activation is not mediated by Cdks 
but by E7-related Rb disruption. The p16 inactivation would not confer any further growth 
promoting effect, because in this cancer the HR-HPV oncogene E7 induces a permanent release 
of E2F from its binding to pRb, leading to continuous cell cycle activation (Nehls, 2008).  
Thus, hypermethylation of p16INK4a promoter gene may be a result of genetic and epigenetic 
events produced during the carcinogenesis steps of cervical cancer development, and when 
occurs, it did not affect the regulation of p16INK4a expression. Moreover, the high p16INK4a 
immunoreactivity with partial promoter hypermethylation needs to be further investigated. 
 
Fig. 6. MSP analysis of the promoter regions of p16INK4a 
The presence of a visible PCR product in lane U indicates the presence of unmethylated 
genes; the presence of a PCR product in lane M indicates the presence of methylated genes. 
Normal lymphocytes DNA (T) was used as a negative control for methylation. Cases 1 and 3 
were methylated at p16INK4a. M: 100 bp ladder. 
7. Expression of E-cadherin in cervical cancer 
Cadherins are a family of cell–cell adhesion molecules which can modulate epithelial 
phenotype and morphogenesis in a variety of tissues. E-cadherin is the major cadherin 
expressed on the surface of normal epithelial cells and plays a pivotal role in maintenance of 
normal adhesion in epithelial cells but has also been shown to suppress tumour invasion 
and participate in cell signalling (Chen, 2003; Virmani, 2001; Ziober, 2001). Cell adhesion is 
mediated through Ca2+-dependent homotypic binding. This transmembrane glycoprotein is 
encoded by CDH1 gene.  
151pb 150pb
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Based on its biological functions, E-cadherin is regarded as an invasion and metastasis 
suppressor. Loss of E-cadherin expression or function correlates with increased invasiveness 
and metastasis in carcinomas of several anatomical sites (Chen, 2003; Virmani, 2001). E-
cadherin-mediated cell adhesion system is inactivated by multiple mechanisms. It may be 
inactivated as a result of genetic alteration, reduced gene expression, changes of other 
cadherin–catenin complexes or posttranslational modification of the protein leading to 
cytoplasmic delocalization (Widschwendter, 2004; Oki, 2007).  
The expression of E-cadherin is impaired as squamous intraepithelial lesions progress to 
squamous cervical carcinoma (Laird, 2003). In cervical cancer, the presence and localisation 
of cytoplasmic E-cadherin were significantly correlated with CIN grade. In invasive types, 
the expression of E-cadherin was significantly reduced (Hirohashi, 1998) and this is mainly 
due to gene silencing by methylation processes (Nehls, 2008).  
E-cadherin expression, as well as p16INK4a expression, is usually used in cervical neoplasia 
diagnosis. In squamous cervical epithelium, E-cadherin is predominantly found at the cell-
to-cell borders in the basal and parabasal cell layers (Laird, 2003). However, E-cadherin 
expression is reduced during tumour progression and metastasis, and associated with poor 
prognosis in a variety of cancers (Karayiannakis, 1998; Sulzer, 1998; Zheng, 1999). A 
representative E-cadherin immunohistochemical staining in epidermoid carcinoma is given 
in Figure 7. 
Reported data showed that E-cadherin is moderately expressed in about 85% of informative 
cases with a main localisation at the cell membrane and cytoplasm (El Hamdani, 2010). 
Decrease or loss of E-cadherin expression is a common feature of many human epithelial 
cancers, including cervical cancer, although a decreased expression of this molecule has 
been described in metastasis, but not primary tumours (Carico, 2001).  
 
Moderate membranous staining of E-cadherin 
Fig. 7. Representative E-cadherin immunohistochemical staining in epidermoid carcinoma 
sample 
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It’s widely accepted that hypermethylation plays a critical role in gene silencing. Promoter 
hypermethylation has been proposed as an explanation for the decrease of E-cadherin 
expression (Chen, 2003, Graff, 2000) and was even suggested as a potential marker for 
identifying cervical cancer patients at high risk for relapse (Widschwendter, 2004). 
Thus, methylation status of E-cadherin promoter has been studied to understand the 
implication of this gene silencing in cervical cancer development. Methylatio status was 
mainly studied using MSP analysis, as shown in Figure 8. Reported data showed that less 
than 50% of cervical cancer cases exhibited E-cadherin promoter hypermethylation at their 
CpG islands (Chen, 2003, Dong, 2001; Narayan, 2003; Attaleb, 2009). Moreover, E-cadherin 
promoter was also hypermethylated in 3 cervical cell lines (HeLa, SiHa and C33A) (Attaleb, 
2009). Thus, partial methylation of the E-cadherin gene promoter leads to down-regulate the 
gene expression. 
 
 
 
Fig. 8. MSP analysis of the promoter regions of p16INK4a 
The presence of a visible PCR product in lane U indicates the presence of unmethylated 
genes; the presence of a PCR product in lane M indicates the presence of methylated genes. 
Normal lymphocytes DNA (T) was used as a negative control for methylation. Case 4 was 
unmethylated at E-cadherin. M: 100 bp ladder. 
8. Epigenetic based therapy 
In tumours, epigenetic silencing of genes involved in DNA damage response pathways, 
such as cell cycle control, apoptosis signalling and DNA repair, has the potential to 
influence drug resistance and clinical outcome following therapy (Teodoridis, 2004). 
Promoter hypermethylation and histone hypoacetylation contribute to this transcriptional 
inactivation. It is possible to reverse silencing using small molecule inhibitors. Such 
compounds, that can reverse this epigenetic inactivation, show anti tumour activity and 
can increase the sensitivity of drug resistant preclinical tumour models (Teodoridis, 2004). 
Hypomethylating and hyperacetylating drugs, HDAC (histone deacetylase) and DNMT 
inhibitors, can reverse epigenetic silencing and improve the cancer therapy (Hidemi, 
2011). 
The targeting of epigenetic pathways is an attractive therapeutic strategy and current 
clinical trials aim to improve efficacy of DNA hypomethylating drugs for e.g. by 
combination with standard chemotherapy. Key components in the regulation of DNA 
97 pb 
116 pb 
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methylation are DNA methyltransferases (DNMT1, 2, 3A and 3B) and methyl CpG-binding 
proteins, which recognize methyl cytosine residues and recruit transcriptional repressor 
complexes, including histone deacetylases (HDAC). Because of the interdependence of 
epigenetic processes, combinations of these approaches may have maximum clinical efficacy 
(Ferguson, 2011). 
Epigenetic therapy leads to gene reactivation in primary tumours of cervical cancer patients. 
A number of these reactivated genes have a definitive role as tumour suppressors (De la 
Cruz-Hernández, 2011). 
Hydralazine, a demethylating agent, was administrated in different doses to cohorts of 
previously untreated patients with histological diagnosis of cervical cancer in a phase I 
study. Hydralazine at doses between 50 and 150 mg/day is well tolerated and effective to 
demethylate and reactivate the expression of tumour suppressor genes without affecting 
global DNA methylation (Zambrano, 2005). 
Valproic acid, an HDAC inhibitor, exerted a growth inhibitory effect on cervical cancer cell 
line: HeLa, SiHa and CaSki (De la Cruz-Hernandez, 2007; Chen, 2006). These drugs led to an 
increase of p53 transcription, and increase its stabilisation due to acetylation at lysines 273 
and 282, protecting it from degradation by E6 (CruzHernandez, 2007). Valproic acid impede 
Akt1 and Akt2 expression, which leads to Akt deactivation and apoptotic cell death 
mediated through the caspase dependent pathway (Chen, 2006). 
The combined antineoplastic effect of the DNA methylation inhibitor hydralazine and the 
histone deacetylase inhibitor valproic acid leads to increase in the cytotoxicity of cisplatin, 
adriamycin or gemcitabine in human cervical cancer cell lines (ChavezBlanco, 2006). 
Also, epigenetic profiling using DNA methylation and histone analysis, can provide useful 
information for translational purposes, with a special emphasis on the potential use of DNA 
methylation marks for early disease detection and prognosis (Park, 2011) and for effective 
treatment strategies (Watanabe, 2010). 
9. Conclusion 
Identification of relevant biomarkers for early and specific diagnosis as well as the 
identification of promising therapeutic targets for molecular targeted therapy is a key role to 
improve cancer management worldwide.  
In cervical cancer, even the importance of combined cytology and HPV testing, the use of 
epigenetic alterations as biomarkers will be of a great interest to enhance cervical diagnosis. 
Since alterations of the cellular epigenome usually precede morphologic changes and 
genetic alterations, identification of related aberrant DNA methylation profiles according to 
specific anatomopathologic status may serve as a reasonable early diagnostic marker for 
cervical cancer diagnosis. 
Moreover, the crucial role of epigenetic alterations at an early stage in the carcinogenesis 
may be promising targets for the prevention or treatment of cancer. Thus, understanding the 
epigenetic derepression of oncogenes, or cancer-promoting genes, would be important for 
the development of epigenetic-based therapies used in combination with other therapies for 
cervical cancer treatment. 
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